Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF

被引:8
|
作者
Romiti, Giulio Francesco [1 ,2 ,3 ]
Proietti, Marco [4 ,5 ]
Corica, Bernadette [1 ,2 ,3 ]
Bonini, Niccolo [1 ,2 ,6 ]
Boriani, Giuseppe [6 ]
Huisman, Menno V. [7 ]
Lip, Gregory Y. H. [1 ,2 ,8 ]
机构
[1] Liverpool John Moores Univ, Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[5] IRCCS Ist Clin Sci Maugeri, Div Subacute Care, Milan, Italy
[6] Univ Modena & Reggio Emilia, Policlin Modena, Div Cardiol, Dept Biomed Metab & Neural Sci, Modena, Italy
[7] Leiden Univ, Dept Thrombosis & Hemostasis, Med Ctr, Leiden, Netherlands
[8] Aalborg Univ, Danish Ctr Clin Hlth Serv Res, Dept Clin Med, Aalborg, Denmark
来源
关键词
anticoagulation; atrial fibrillation; clinical complexity; elderly individuals; outcomes; EUROBSERVATIONAL RESEARCH-PROGRAM; ANTICOAGULATION; STROKE; IMPACT; BARRIERS; OUTCOMES; PATHWAY; CARE;
D O I
10.1161/JAHA.123.030565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Clinical risk factors are common among patients with atrial fibrillation (AF), but there are still limited data on their association with oral anticoagulant (OAC) treatment patterns and major outcomes. We aim to analyze the association between clinical risk phenotypes on AF treatment patterns and the risk of major outcomes. METHODS AND RESULTS: The GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation) phase 2 and 3 registries enrolled patients with a recent diagnosis of AF between 2011 and 2016. We defined 4 features of clinical risk among patients with CHA(2)DS(2)-VASc >= 2: elderly individuals (aged >= 80 years), chronic kidney disease (estimated glomerular filtration rate <45 mL/min), history of stroke, and history of bleeding. We analyzed the odds of receiving OAC and the risk of OAC discontinuation and adverse events at follow-up according to specific combinations and cumulative burden of these features. Primary outcome was the composite of all-cause death, thromboembolism, and major bleeding. Among 28 891 (mean +/- SD age, 70.1 +/- 10.5 years; 45.5% women) patients included, 10 797 (37.3%) had at least 1 clinical risk feature. OAC use was lower among patients in the elderly group (odds ratio [OR], 0.85 [95% CI, 0.75-0.96]), those with history of both stroke and bleeding (OR, 0.45 [95% CI, 0.35-0.56]), and those with multiple features (OR, 0.71 [95% CI, 0.62-0.82]). Increasing burden of clinical risk features was associated with OAC discontinuation, with highest magnitude in those with >= 3 features (hazard ratio [HR], 1.68 [95% CI, 1.31-2.15]). Groups with increasingly complex clinical risk phenotypes were associated with the occurrence of the primary composite outcome, with the highest figures observed for groups with a history of both stroke and bleeding (adjusted HR, 2.36 [95% CI, 1.83-3.04]) and multiple features (adjusted HR, 2.86 [95% CI, 2.52-3.25]). CONCLUSIONS: In patients with AF, clinical risk phenotypes are multifaceted and heterogenous, and they are associated with differences in stroke prevention and worse prognosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
    Menno V. Huisman
    Christine Teutsch
    Shihai Lu
    Hans-Christoph Diener
    Sergio J. Dubner
    Jonathan L. Halperin
    Chang-Sheng Ma
    Kenneth J. Rothman
    Ragna Lohmann
    Venkatesh Kumar Gurusamy
    Dorothee B. Bartels
    Gregory Y. H. Lip
    Clinical Research in Cardiology, 2022, 111 : 548 - 559
  • [32] Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
    Huisman, Menno, V
    Teutsch, Christine
    Lu, Shihai
    Diener, Hans-Christoph
    Dubner, Sergio J.
    Halperin, Jonathan L.
    Ma, Chang-Sheng
    Rothman, Kenneth J.
    Lohmann, Ragna
    Gurusamy, Venkatesh Kumar
    Bartels, Dorothee B.
    Lip, Gregory Y. H.
    CLINICAL RESEARCH IN CARDIOLOGY, 2022, 111 (05) : 548 - 559
  • [33] Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
    Lip, Gregory Y. H.
    Kotalczyk, Agnieszka
    Teutsch, Christine
    Diener, Hans-Christoph
    Dubner, Sergio J.
    Halperin, Jonathan L.
    Ma, Chang-Sheng
    Rothman, Kenneth J.
    Marler, Sabrina
    Gurusamy, Venkatesh Kumar
    Huisman, Menno, V
    CLINICAL RESEARCH IN CARDIOLOGY, 2022, 111 (05) : 560 - 573
  • [34] Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF
    Halperin, J. L.
    Teutsch, C.
    Huisman, M. V.
    Diener, H. -C.
    Rothman, K. J.
    Ma, C. S.
    Dubner, S. J.
    Zint, K.
    Franca, L. Riou
    Paquette, M.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2018, 39 : 610 - 610
  • [35] Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program
    McIntyre, William F.
    Conen, David
    Olshansky, Brian
    Halperin, Jonathan L.
    Hayek, Emil
    Huisman, Menno V.
    Lip, Gregory Y. H.
    Lu, Shihai
    Healey, Jeff S.
    CLINICAL CARDIOLOGY, 2018, 41 (06) : 744 - 751
  • [36] Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry
    Romiti, Giulio Francesco
    Proietti, Marco
    Bonini, Niccolo
    Ding, Wern Yew
    Boriani, Giuseppe
    Huisman, Menno, V
    Lip, Gregory Y. H.
    ECLINICALMEDICINE, 2023, 55
  • [37] Prescribing of dabigatran etexilate in accordance with the European label for stroke prevention in atrial fibrillation: Findings from the GLORIA-AF Registry
    Lip, G. Y. H.
    Teusch, C.
    Huisman, M. V.
    Diener, H. C.
    Dubner, S. J.
    Ma, C. S.
    Rothman, K. J.
    Elsaesser, A.
    Paquette, M.
    Zint, K.
    Bartels, D.
    Halperin, J. L.
    EUROPEAN HEART JOURNAL, 2017, 38 : 975 - 975
  • [38] Incidence and risk factors for residual adverse events despite anticoagulation in atrial fibrillation: results from phase II/III of the GLORIA-AF registry
    Ding, W. Y.
    Lane, D. A.
    Gupta, D.
    Huisman, M. V.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 516 - 516
  • [39] Implications of renal function on adverse clinical events in patients with atrial fibrillation: a comparative analysis of VKA and NOAC therapy - Insights from the GLORIA-AF Registry Phase III
    Liu, Y.
    Chen, Y.
    Lam, S. H. M.
    Huang, B.
    Chao, T. F.
    Olshansky, B.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [40] Adverse outcomes according to metabolic status in obese and overweight patients with atrial fibrillation: a report from the GLORIA-AF Phase II and III Registry
    Corica, B.
    Romiti, G. F.
    Proietti, M.
    Mei, D. A.
    Boriani, G.
    Chao, T. F.
    Olshansky, B.
    Huisman, M. V.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2023, 44